Use of glucagon-like peptide-1 receptor agonists (GLP1RA) in adults with type 2 diabetes was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.
Question Is the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) associated with increased risk of chronic cough?
Findings In this cohort study of 427 555 individuals who were prescribed a GLP-1RA and 1 614 495 matched individuals who were prescribed a different second-line diabetes medication, GLP-1RA treatment was associated with a higher adjusted hazard ratio of new chronic cough. This association was independent of gastroesophageal reflux disease diagnosis.
Meaning The study findings suggest that patients who use GLP-1RAs have an increased risk of chronic cough, suggesting further exploration of the strength of this association and pharmacologic mechanisms.








